Companies whose shares are expected to trade actively in today’s session are Repros Therapeutics Inc (NASDAQ:RPRX), Five Below Inc (NASDAQ:FIVE), Research In Motion Ltd (NASDAQ:BBRY) (TSE:BB) aka Blackberry, Oncolytics Biotech, Inc. (NASDAQ:ONCY) (TSE:ONC), PVH Corp (NYSE:PVH) and Genworth Financial Inc (NYSE:GNW).
Repros Therapeutics Inc (NASDAQ:RPRX): The pharmaceutical company announced that its flagship molecule for testosterone disorder demonstrated to bring men’s testosterone level to a normal range in preliminary research. The drug met its primary objective. Shares of Repros surged 67.14 percent to $15.27 in the early session.
Five Below Inc (NASDAQ:FIVE): The discount retailer announced a whopping 55 percent increase in its fourth quarter profits at a time when most retailers continue to struggle. The company’s same store sales improved during the quarter. However, Five Below issued downbeat guidance for the current quarter. Shares slipped 3.94 percent to $37.62 in early trading.
Research In Motion Ltd (NASDAQ:BBRY) (TSE:BB): Despite lukewarm response to its Z10 device in the United States, the BlackBerry maker surprised Wall Street by announcing a fourth quarter profit. The company also demonstrated a strong financial position. It was the first period that included the sales of new devices Z10 and Q10. Shares rose 2.35 percent to $14.91 in the early session.
Oncolytics Biotech, Inc. (NASDAQ:ONCY) (TSE:ONC): The biotechnology company said the secondary study of its Reolysin drug showed positive results. Reolysin can be used to treat squamous cell carcinoma in lungs. Shares jumped 7.36 percent to $3.21 in early market trading.
PVH Corp (NYSE:PVH): The apparel maker’s fourth quarter profits doubled, handily beating Wall Street’s estimates. Its Calvin Klein and Tommy Hilfiger brands showed strong sales growth. However, the company issued pessimistic guidance for the current quarter and full year. Shares tanked 4.81 percent to $107.36 in early trading.
Genworth Financial Inc (NYSE:GNW): In an attempt to sell non-core assets, the insurer announced the sale of its wealth management division to Genstar Capital and Aquiline Capital Partners in a $412 million deal. Shares were down 1.28 percent to $10.05 in the early session.
